Literature DB >> 19505532

GSK-3beta and control of glucose metabolism and insulin action in human skeletal muscle.

T P Ciaraldi1, L Carter, S Mudaliar, R R Henry.   

Abstract

The involvement of the beta-isoform of glycogen synthase kinase (GSK-3) in glucose metabolism and insulin action was investigated in cultured human skeletal muscle cells. A 60% reduction in GSK-3beta protein expression was attained by treatment with siRNA; GSK-3alpha expression was unaltered. GSK-3beta knockdown did not influence total glycogen synthase (GS) activity, but increased the phosphorylation-dependent activity (fractional velocity-FV) in the basal state. Insulin responsiveness of GSFV was doubled by GSK-3beta knockdown (p<0.05). Basal rates of glucose uptake (GU) were not significantly influenced by GSK-3beta knockdown, while insulin stimulation of GU was increased. Improvements in insulin action on GS and GU did not involve changes in protein expression of either IRS-1 or Akt 1/2. Maximal insulin stimulation of phosphorylation of Akt was unaltered by GSK-3beta knockdown. Unlike GSK-3alpha, GSK-3beta directly regulates both GS activity in the absence of added insulin and through control of insulin action. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505532      PMCID: PMC2819161          DOI: 10.1016/j.mce.2009.05.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  48 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

Review 2.  GSK3 inhibitors: development and therapeutic potential.

Authors:  Philip Cohen; Michel Goedert
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

3.  The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity.

Authors:  Michael Gaster; Ingrid Petersen; Kurt Højlund; Pernille Poulsen; Henning Beck-Nielsen
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

4.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Authors:  David B Ring; Kirk W Johnson; Erik J Henriksen; John M Nuss; Dane Goff; Tyson R Kinnick; Sylvia T Ma; John W Reeder; Isa Samuels; Trina Slabiak; Allan S Wagman; Mary-Ellen Wernette Hammond; Stephen D Harrison
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

Review 5.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.

Authors:  J R Woodgett
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

Review 6.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.

Authors:  Allan S Wagman; Kirk W Johnson; Dirksen E Bussiere
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

7.  Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria.

Authors:  Gautam N Bijur; Richard S Jope
Journal:  Neuroreport       Date:  2003-12-19       Impact factor: 1.837

8.  Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes.

Authors:  Kurt Højlund; Peter Staehr; Bo Falck Hansen; Kevin A Green; D Grahame Hardie; Erik A Richter; Henning Beck-Nielsen; Jørgen F P Wojtaszewski
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

9.  Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats.

Authors:  Gary W Cline; Kirk Johnson; Werner Regittnig; Pascale Perret; Effie Tozzo; Linda Xiao; Christine Damico; Gerald I Shulman
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

10.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle.

Authors:  Svetlana E Nikoulina; Theodore P Ciaraldi; Sunder Mudaliar; Leslie Carter; Kirk Johnson; Robert R Henry
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

View more
  9 in total

1.  Transcriptional regulation of pig GYS1 gene by glycogen synthase kinase 3β (GSK3β).

Authors:  Yilin Wang; Yan Wang; Tao Zhong; Jiazhong Guo; Li Li; Hongping Zhang; Linjie Wang
Journal:  Mol Cell Biochem       Date:  2016-10-26       Impact factor: 3.396

2.  Identification of porcine glycogen synthase kinase 3α (GSK-3α) gene and its association with carcass traits.

Authors:  Linjie Wang; Yan Wang; Tao Zhong; Li Li; Hongping Zhang; Yuanzhu Xiong
Journal:  Mol Cell Biochem       Date:  2013-01-29       Impact factor: 3.396

3.  Myotubes derived from human-induced pluripotent stem cells mirror in vivo insulin resistance.

Authors:  Salvatore Iovino; Alison M Burkart; Laura Warren; Mary Elizabeth Patti; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

4.  Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex.

Authors:  Nida Haider; Jasmin Lebastchi; Ashok Kumar Jayavelu; Thiago M Batista; Hui Pan; Jonathan M Dreyfuss; Ivan Carcamo-Orive; Joshua W Knowles; Matthias Mann; C Ronald Kahn
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

5.  Alteration in amyloid β42, phosphorylated tau protein, interleukin 6, and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats: correlation of amyloid β42 with changes in glucose metabolism.

Authors:  You Zhou; Ying Zhao; Hailong Xie; Yan Wang; Lin Liu; Xinjia Yan
Journal:  Behav Brain Funct       Date:  2015-08-14       Impact factor: 3.759

6.  Protective effects of asiatic acid in a spontaneous type 2 diabetic mouse model.

Authors:  Wen Sun; Guangyuan Xu; Xuan Guo; Guangbin Luo; Lili Wu; Yi Hou; Xiangyu Guo; Jingxin Zhou; Tunhai Xu; Lingling Qin; Yixin Fan; Li Han; Motlalepula Matsabisa; Xuesheng Ma; Tonghua Liu
Journal:  Mol Med Rep       Date:  2017-06-02       Impact factor: 2.952

7.  Human amniotic mesenchymal stem cells-conditioned medium protects mice from high-fat diet-induced obesity.

Authors:  Hui-Lan Tan; Xiao-Hui Guan; Min Hu; Jie Wu; Rong-Zhen Li; Ling-Fang Wang; Hou-Da Huang; Zhen-Ping Yu; Xiao-Yu Wang; Yun-Fei Xiao; Ke-Yu Deng; Hong-Bo Xin
Journal:  Stem Cell Res Ther       Date:  2021-06-26       Impact factor: 6.832

8.  Alternative splicing of the porcine glycogen synthase kinase 3β (GSK-3β) gene with differential expression patterns and regulatory functions.

Authors:  Linjie Wang; Bo Zuo; Dequan Xu; Zuqing Ren; Hongping Zhang; Xuewei Li; Minggang Lei; Yuanzhu Xiong
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone.

Authors:  Alan Fappi; Juliana de Carvalho Neves; Leandro Nunes Sanches; Pedro Victor Massaroto E Silva; Guilherme Yuiti Sikusawa; Thayane Pereira Correa Brandão; Gerson Chadi; Edmar Zanoteli
Journal:  Cells       Date:  2019-05-01       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.